Ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone in patients with previously untreated non‐germinal centre B‐cell‐like diffuse large B‐cell lymphoma: A Chinese subgroup analysis of the phase III PHOENIX trial-Reference-Cited by-同舟云学术

Ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone in patients with previously untreated non‐germinal centre B‐cell‐like diffuse large B‐cell lymphoma: A Chinese subgroup analysis of the phase III PHOENIX trial

Published:2022-08-30 Issue:4 Volume:3 Page:1154-1164
ISSN:2688-6146
Container-title:eJHaem
language:en
Short-container-title:eJHaem

Author:

Zhu Jun¹,Hong Xiaonan²,Song Yu Qin¹,Hodkinson Brendan³,Balasubramanian Sriram⁴,Wang Songbai⁵,Zhang Qingyuan⁶,Shi Yuankai⁷^ORCID,Huang Huiqiang⁸,Zhang Huilai⁹,Zhu Yan¹⁰,Shreeve Stephen Martin¹¹,Sun Steven¹²,Wang Ze¹³,Wang Xiaocan¹³,Fan Yue¹⁴,Wilson Wyndham¹⁵,Vermeulen Jessica¹⁶

Affiliation:

1. Beijing University Cancer Hospital and Institute Beijing China

2. Fudan University Cancer Hospital Shanghai China

3. Oncology Translational Research Janssen Research and Development Spring House Pennsylvania USA

4. Oncology Translational Research Janssen Research and Development San Diego California USA

5. Oncology Translational Research Janssen Research and Development Raritan New Jersey USA

6. Affiliated Cancer Hospital of Harbin Medical University Harbin China

7. National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs Beijing China

8. Sun Yat‐sen University Cancer Center Guangzhou China

9. Tianjin Cancer Hospital Heping China

10. Janssen Research and Development Raritan New Jersey USA

11. Clinical Oncology Janssen Research and Development San Diego California USA

12. Clinical Biostats Janssen Research and Development Raritan New Jersey USA

13. Xian Janssen Pharmaceuticals Medical Affairs Beijing China

14. Oncology Translational Research Janssen Research and Development Shanghai China

15. National Cancer Institute National Institutes of Health Bethesda Maryland USA

16. Clinical Oncology Janssen Research and Development Leiden The Netherlands

Funder

Janssen Research and Development

Publisher